Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer

  • Authors:
    • Jian Gong
    • Asahiro Morishita
    • Kazutaka Kurokohchi
    • Joji Tani
    • Kiyohito Kato
    • Hisaaki Miyoshi
    • Hideyuki Inoue
    • Mitsuyoshi Kobayashi
    • Shi Liu
    • Masayuki Murota
    • Akemi Muramatsu
    • Kunihiko Izuishi
    • Yasuyuki Suzuki
    • Hirohito Yoshida
    • Naohito Uchida
    • Kazushi Deguchi
    • Hisakazu Iwama
    • Ichiro Ishimaru
    • Tsutomu Masaki
  • View Affiliations

  • Published online on: January 1, 2010     https://doi.org/10.3892/ijo_00000480
  • Pages: 101-106
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Our study used protein array technology to analyze the expression status of various activated receptor tyrosine kinases (RTKs) in gastric carcinoma; then, we sought to discover an effective therapeutic receptor tyrosine kinase for this disease and investigated the anti-tumor mechanism of the therapeutic RTK. In addition to the expressions of activated RTKs in human gastric cancer and adjacent normal mucosa, the expression of activated RTKs in gastric cancer cell lines, MKN74, MKN45, MKN7 and MKN1, were also studied. The RTKs activated in gastric cancer tissue are EGFR, ErbB2, FGFR1, FGFR2α insulin R, and EphA4. Among the RTKs activated in gastric cancer tissues, EGFR and ErbB2 were also activated in all gastric cell lines examined in this study. A subsequent in vitro experiment using subcutaneous gastric cancer-bearing athymic nude mice demonstrated that the ErbB2-targeting drug trastuzumab markedly suppressed the growth of gastric cancer. Moreover, using an angiogenesis protein array, the expressions of Ang I, FGF-α, FGF-β TGF-β and IL-8 in MKN74 xenograft tumors were found to be significantly reduced by treatment with trastuzumab, indicating that trastuzumab may inhibit the expression of angiogenic molecules in MKN74 cells in vivo. These data suggest that ErbB2 is activated in gastric cancer, and the ErbB2-targeting drug trastuzumab may be related to the reduction of Ang 1, FGFα, FGFβ, TGFα and IL-8.

Related Articles

Journal Cover

January 2010
Volume 36 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Gong, J., Morishita, A., Kurokohchi, K., Tani, J., Kato, K., Miyoshi, H. ... Masaki, T. (2010). Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer. International Journal of Oncology, 36, 101-106. https://doi.org/10.3892/ijo_00000480
MLA
Gong, J., Morishita, A., Kurokohchi, K., Tani, J., Kato, K., Miyoshi, H., Inoue, H., Kobayashi, M., Liu, S., Murota, M., Muramatsu, A., Izuishi, K., Suzuki, Y., Yoshida, H., Uchida, N., Deguchi, K., Iwama, H., Ishimaru, I., Masaki, T."Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer". International Journal of Oncology 36.1 (2010): 101-106.
Chicago
Gong, J., Morishita, A., Kurokohchi, K., Tani, J., Kato, K., Miyoshi, H., Inoue, H., Kobayashi, M., Liu, S., Murota, M., Muramatsu, A., Izuishi, K., Suzuki, Y., Yoshida, H., Uchida, N., Deguchi, K., Iwama, H., Ishimaru, I., Masaki, T."Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer". International Journal of Oncology 36, no. 1 (2010): 101-106. https://doi.org/10.3892/ijo_00000480